COINTURK FINANCECOINTURK FINANCECOINTURK FINANCE
  • Investing
  • Technology News
  • Business
  • Fintech
  • Startup
  • About Us
  • Contact
Search
Health
  • About Us
  • Contact
Entertainment
  • Investing
  • Business
  • Fintech
  • Startup
© 2024 BLOCKCHAIN IT. >> COINTURK FINANCE
Powered by LK SOFTWARE
Reading: SeaBeLife Gains €2 Million to Propel Drug Development
Share
Font ResizerAa
COINTURK FINANCECOINTURK FINANCE
Font ResizerAa
Search
  • Investing
  • Technology News
  • Business
  • Fintech
  • Startup
  • About Us
  • Contact
Follow US
© 2025 BLOCKCHAIN Information Technologies. >> COINTURK FINANCE
Powered by LK SOFTWARE
Track all markets on TradingView
COINTURK FINANCE > Startup > SeaBeLife Gains €2 Million to Propel Drug Development
Startup

SeaBeLife Gains €2 Million to Propel Drug Development

Overview

  • SeaBeLife raised €2 million to develop drug therapy innovations.

  • Targeted conditions have significant demand for improved treatment solutions.

  • Advances aim to address complex disease mechanisms with dual-pathway approaches.

COINTURK FINANCE
COINTURK FINANCE 2 hours ago
SHARE

French biotech company SeaBeLife has successfully raised €2 million in a pre-Series A funding round to fuel development in its drug pipeline. Positioned in Roscoff, the company plans to initiate clinical trials by 2026. This new funding excites potential for SeaBeLife’s ongoing therapeutic projects, capturing attention from several investors eager to support innovation in medical science.

Contents
Why Is the New Funding Significant?What Are SeaBeLife’s Next Steps?

SeaBeLife’s strategy revolves around small molecules intended to target both necroptosis and ferroptosis, two cell death mechanisms tied to numerous diseases. By leveraging such a dual-target method, still nonexistent in the market, the company aims to enhance organ protection therapies. Recent history shows an increasing interest in multi-target drug developments like these, fostering potential treatment advances for diseases with intricate pathological mechanisms.

Why Is the New Funding Significant?

The fresh investment, capably led by existing investor iXLife, is bolstered by new participants INEXT and Femmes Business Angels, underscoring confidence in SeaBeLife’s innovative strategy.

“The renewed backing from our longstanding investors, together with the addition of new partners, is a clear signal of confidence in our vision,”

expressed Morgane Rousselot, CEO of SeaBeLife. The financing will support their two leading therapeutic initiatives targeting dry AMD (NASDAQ:AMD) and severe acute hepatitis, both aiming to address a high demand for new solutions.

What Are SeaBeLife’s Next Steps?

The company is now preparing a Series A funding round to maintain its development momentum. Already over €9 million has been gathered through equity and public financing, including support from significant names like Bpifrance. Currently, SeaBeLife’s lead candidates, SBL03 for dry AMD and SBL01 for severe hepatitis, are in the preclinical stage, showing promising efficacy data. Such progress hints at a potentially lucrative and impactful presence in a market with limited treatment options.

Alongside notable success in financing, SeaBeLife enjoys collaborative efforts with INEXT and Femmes Business Angels, each bringing unique insights and strategic value to the firm’s initiatives. With noteworthy collaborators such as Marie-Pierre Sbardella on the Strategic Committee, SeaBeLife is reinforcing its operational depth and market positioning. Through relationships with these strategic partners, the company lays a robust foundation for its forthcoming clinical phases.

SeaBeLife’s approach may diversify pharmaceutical solutions for conditions like dry AMD and hepatitis.

“This fundraising is a decisive step towards clinical trials,”

Rousselot emphasized, as they prepare to transition from preclinical phases to tangible market applications. The ambition to pioneer new treatments using dual pathways is informed by comprehensive research within the bioscience landscape.

Evaluating the landscape of innovations in treatment strategies, SeaBeLife stands out for its strategic insight into uncharted territories of cellular biology. With underserved patient populations potentially benefitting from their discoveries, the company could fill critical spaces in current therapy offerings. Attention is therefore drawn from investors and industry experts keen to see how these experimental treatments progress.

SeaBeLife continues to set promising expectations within the biotechnology field. By addressing inadequacies within existing therapy options and cementing robust investor relations, the company advances its objective to resolve complex disease challenges. This progression indicates its ambition to reinforce its place at the forefront of translational research and biopharmaceutical development. It remains crucial for stakeholders to track SeaBeLife’s journey as it potentially broadens available solutions for multifaceted conditions.

You can follow our news on Telegram and Twitter (X)
Disclaimer: The information contained in this article does not constitute investment advice. Investors should be aware that cryptocurrencies carry high volatility and therefore risk, and should conduct their own research.

You Might Also Like

Investors Flood Nscale with $433M Pre-Series C Funding

Dott Expands E-bike Fleet in Paris with New Segway Model

Serena Expands Venture Ambitions with €200 Million Fund Under Serena IV

Investors Rally Behind AI as Key Driver in Venture Capital Strategies

HoneyBook Acquires Fine.dev to Accelerate AI-Powered Development

Share This Article
Facebook Twitter Copy Link Print
Previous Article Fifth Third Bank and OrthoAlliance Address Healthcare’s Revenue Challenges
Next Article Dott Expands E-bike Fleet in Paris with New Segway Model
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Latest News

Fifth Third Bank and OrthoAlliance Address Healthcare’s Revenue Challenges
COINTURK FINANCE COINTURK FINANCE 2 hours ago
SMBs Demand Accelerated Payments As Banks Favor Large Enterprises
COINTURK FINANCE COINTURK FINANCE 2 hours ago
Spotify Shifts Leadership as Daniel Ek Takes on New Role
COINTURK FINANCE COINTURK FINANCE 3 hours ago
Nubank Seeks U.S. National Bank Charter to Expand its Digital Presence
COINTURK FINANCE COINTURK FINANCE 10 hours ago
Fed Rate Cuts Influence Housing Market Prospects
COINTURK FINANCE COINTURK FINANCE 11 hours ago
//

COINTURK was launched in March 2014 by a group of tech enthusiasts focused on the internet and new technologies.

CATEGORIES

  • Investing
  • Business
  • Fintech
  • Startup

OUR PARTNERS

  • COINTURK NEWS
  • BH NEWS
  • NEWSLINKER

OUR COMPANY

  • About Us
  • Contact
COINTURK FINANCECOINTURK FINANCE
Follow US
© 2025 BLOCKCHAIN Information Technologies. >> COINTURK FINANCE
Powered by LK SOFTWARE
Welcome Back!

Sign in to your account

Lost your password?